LXEO Latest Press Releases

-- October 19, 2026 --

Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM Globe Newswire 7:00 AM

-- October 8, 2026 --

Lexeo Therapeutics to Participate in the Chardan Healthcare Conference Globe Newswire 7:00 AM

-- October 1, 2026 --

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS) Globe Newswire 9:00 AM

-- September 23, 2026 --

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich Ataxia PRNewswire 8:00 AM

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum Globe Newswire 7:00 AM

-- September 22, 2026 --

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia Globe Newswire 7:00 AM

-- September 2, 2026 --

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September Globe Newswire 7:00 AM

-- August 12, 2026 --

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights Globe Newswire 7:00 AM

-- August 5, 2026 --

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy Globe Newswire 7:00 AM

-- June 17, 2026 --

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia Globe Newswire 4:01 PM

-- June 15, 2026 --

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes